Skip to content
Screener

Edgewise Therapeutics, Inc. EWTX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$207M+6.7%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$11.2M-15.6%
Cytokinetics logo
CytokineticsCYTK
$21.04M+7.4%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$12.08M+5.4%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$5.03M-1.5%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$2.23M+15.0%

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.73B+245%
Enterprise value$4.7B+253%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:09 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056713
AssetsAs of / March 31, 2026 / (unaudited)As of / December 31, 2025
Accounts payable$7,293$6,006
Accrued compensation5,67812,430
Accrued other expenses8,5557,920
Operating lease liability, current portion1,0171,014
Total current liabilities22,54327,370
Operating lease liability, net of current portion2,7762,976
Total liabilities25,31930,346
Commitments and contingencies (see note 5)

Item 1. Financial Statements (Unaudited)

FAQ

What is Edgewise Therapeutics, Inc.'s operating lease liabilities (current)?
Edgewise Therapeutics, Inc. (EWTX) reported operating lease liabilities (current) of $1.02M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s operating lease liabilities (current) changed year-over-year?
Edgewise Therapeutics, Inc.'s operating lease liabilities (current) increased by 1.6% year-over-year, from $1M to $1.02M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s operating lease liabilities (current)?
Over 3 years (2022 to 2025), Edgewise Therapeutics, Inc.'s operating lease liabilities (current) has grown at a 18.6% compound annual growth rate (CAGR), from $608K to $1.01M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Edgewise Therapeutics, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude